Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt No Debt
AEZS's Cash-to-Debt is ranked higher than
96% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 49.39 vs. AEZS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
AEZS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.44  Med: 5097.33 Max: No Debt
Current: No Debt
Equity-to-Asset 0.10
AEZS's Equity-to-Asset is ranked lower than
89% of the 483 Companies
in the Global Biotechnology industry.

( Industry Median: 0.63 vs. AEZS: 0.10 )
Ranked among companies with meaningful Equity-to-Asset only.
AEZS' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.34  Med: 0.37 Max: 0.98
Current: 0.1
-0.34
0.98
Interest Coverage No Debt
AEZS's Interest Coverage is ranked higher than
97% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AEZS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
AEZS' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: -14.27
Beneish M-Score: -2.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -4498.95
AEZS's Operating Margin % is ranked lower than
89% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -50.65 vs. AEZS: -4498.95 )
Ranked among companies with meaningful Operating Margin % only.
AEZS' s Operating Margin % Range Over the Past 10 Years
Min: -339954.55  Med: -303.55 Max: -37.89
Current: -4498.95
-339954.55
-37.89
Net Margin % -3799.19
AEZS's Net Margin % is ranked lower than
89% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -43.94 vs. AEZS: -3799.19 )
Ranked among companies with meaningful Net Margin % only.
AEZS' s Net Margin % Range Over the Past 10 Years
Min: -150581.82  Med: -129.08 Max: 110.36
Current: -3799.19
-150581.82
110.36
ROE % -211.29
AEZS's ROE % is ranked lower than
91% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: -24.74 vs. AEZS: -211.29 )
Ranked among companies with meaningful ROE % only.
AEZS' s ROE % Range Over the Past 10 Years
Min: -702.59  Med: -128.04 Max: 125.79
Current: -211.29
-702.59
125.79
ROA % -62.82
AEZS's ROA % is ranked lower than
75% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: -21.99 vs. AEZS: -62.82 )
Ranked among companies with meaningful ROA % only.
AEZS' s ROA % Range Over the Past 10 Years
Min: -109.74  Med: -30.25 Max: 11.16
Current: -62.82
-109.74
11.16
ROC (Joel Greenblatt) % -12674.75
AEZS's ROC (Joel Greenblatt) % is ranked lower than
90% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: -218.94 vs. AEZS: -12674.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AEZS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -12674.75  Med: -917.27 Max: -34.37
Current: -12674.75
-12674.75
-34.37
3-Year Revenue Growth Rate -72.30
AEZS's 3-Year Revenue Growth Rate is ranked lower than
88% of the 435 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. AEZS: -72.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AEZS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -23.1 Max: 131.2
Current: -72.3
0
131.2
3-Year EBITDA Growth Rate -49.50
AEZS's 3-Year EBITDA Growth Rate is ranked lower than
91% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. AEZS: -49.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AEZS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -18.7 Max: 183.9
Current: -49.5
0
183.9
3-Year EPS without NRI Growth Rate -40.10
AEZS's 3-Year EPS without NRI Growth Rate is ranked lower than
83% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. AEZS: -40.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AEZS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -15.4 Max: 65.1
Current: -40.1
0
65.1
GuruFocus has detected 2 Warning Signs with AEterna Zentaris Inc $AEZS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AEZS's 10-Y Financials

Financials (Next Earnings Date: 2017-03-30)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

AEZS Guru Trades in Q1 2016

Jim Simons 516,833 sh (+5.94%)
» More
Q2 2016

AEZS Guru Trades in Q2 2016

Jim Simons 445,333 sh (-13.83%)
» More
Q3 2016

AEZS Guru Trades in Q3 2016

Jim Simons 405,333 sh (-8.98%)
» More
Q4 2016

AEZS Guru Trades in Q4 2016

Jim Simons 308,033 sh (-24.00%)
» More
» Details

Insider Trades

Latest Guru Trades with AEZS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 3741
Compare:OTCPK:CVALF, OTCPK:ONCYF, NAS:OHRP, AMEX:IBIO, NAS:XOMA, NAS:DFFN, NAS:CSBR, NAS:TPIV, OTCPK:VBIO, OTCPK:BIOAF, NAS:CYTX, NAS:APOP, OTCPK:FENCF, NAS:XBIO, OTCPK:RGRX, OTCPK:EMIS, AMEX:OGEN, OTCPK:BLEVF, AMEX:MSTX, NAS:RPRX » details
Traded in other countries:AEZ.Canada, ET82.Germany,
AEterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing novel treatments in oncology, endocrinology and women's health.

AEterna Zentaris Inc is incorporated on September 12, 1990 under the Canada Business Corporations Act (the CBCA) and continues to be governed by the CBCA. The Company is an oncology and endocrinology drug development company investigating treatments for various unmet medical needs. Its pipeline encompasses compounds at all stages of development from drug discovery through to marketed products. Its oncology pipeline also encompasses other earlier-stage programs, including AEZS-112, an oral anticancer agent which involves three mechanisms of action such as tubulin, topoisomerase II and angiogenesis inhibition which has completed a Phase 1 trial in advanced solid tumors and lymphoma. Additionally, several novel targeted anticancer candidates such as AEZS-120, a live recombinant oral tumor vaccine candidate, as well as PI3K/Erk inhibitors, including AEZS-129, AEZS-134 and AEZS-136, are currently in preclinical development. In endocrinology, the Company is preparing the filing of an NDA in the U.S. for the registration of AEZS-130, an oral ghrelin agonist, as a diagnostic test for adult growth hormone deficiency (AGHD). A Phase 3 trial under a SPA with the FDA has been completed in this indication. Furthermore, AEZS-130 is in a Phase 2A trial for the treatment of cancer-induced cachexia.

Ratios

vs
industry
vs
history
PE Ratio 0.32
AEZS's PE Ratio is ranked higher than
98% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 26.13 vs. AEZS: 0.32 )
Ranked among companies with meaningful PE Ratio only.
AEZS' s PE Ratio Range Over the Past 10 Years
Min: 0.26  Med: 5.32 Max: 18.35
Current: 0.32
0.26
18.35
PE Ratio without NRI 0.32
AEZS's PE Ratio without NRI is ranked higher than
98% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 26.61 vs. AEZS: 0.32 )
Ranked among companies with meaningful PE Ratio without NRI only.
AEZS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0.26  Med: 15.48 Max: 29.98
Current: 0.32
0.26
29.98
PB Ratio 9.44
AEZS's PB Ratio is ranked lower than
82% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. AEZS: 9.44 )
Ranked among companies with meaningful PB Ratio only.
AEZS' s PB Ratio Range Over the Past 10 Years
Min: 0.58  Med: 2.69 Max: 44.26
Current: 9.44
0.58
44.26
PS Ratio 33.47
AEZS's PS Ratio is ranked lower than
76% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.96 vs. AEZS: 33.47 )
Ranked among companies with meaningful PS Ratio only.
AEZS' s PS Ratio Range Over the Past 10 Years
Min: 0.68  Med: 4.69 Max: 3761.9
Current: 33.47
0.68
3761.9
Current Ratio 3.98
AEZS's Current Ratio is ranked higher than
56% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. AEZS: 3.98 )
Ranked among companies with meaningful Current Ratio only.
AEZS' s Current Ratio Range Over the Past 10 Years
Min: 0.92  Med: 3.38 Max: 50.67
Current: 3.98
0.92
50.67
Quick Ratio 3.98
AEZS's Quick Ratio is ranked higher than
58% of the 583 Companies
in the Global Biotechnology industry.

( Industry Median: 3.24 vs. AEZS: 3.98 )
Ranked among companies with meaningful Quick Ratio only.
AEZS' s Quick Ratio Range Over the Past 10 Years
Min: 0.92  Med: 3.15 Max: 49
Current: 3.98
0.92
49
Days Sales Outstanding 196.22
AEZS's Days Sales Outstanding is ranked lower than
90% of the 405 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. AEZS: 196.22 )
Ranked among companies with meaningful Days Sales Outstanding only.
AEZS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.11  Med: 81.53 Max: 19345
Current: 196.22
14.11
19345

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -241.20
AEZS's 3-Year Average Share Buyback Ratio is ranked lower than
97% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. AEZS: -241.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AEZS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -241.2  Med: -15.9 Max: 0
Current: -241.2
-241.2
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 7.09
AEZS's Price-to-Median-PS-Value is ranked lower than
96% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 0.99 vs. AEZS: 7.09 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AEZS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.13  Med: 0.87 Max: 690
Current: 7.09
0.13
690
Earnings Yield (Greenblatt) % -218.25
AEZS's Earnings Yield (Greenblatt) % is ranked lower than
98% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -6.50 vs. AEZS: -218.25 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AEZS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -227.3  Med: 214.9 Max: 23873.5
Current: -218.25
-227.3
23873.5

More Statistics

Revenue (TTM) (Mil) $0.71
EPS (TTM) $ 9.29
Beta0.89
Short Percentage of Float8.07%
52-Week Range $2.35 - 5.59
Shares Outstanding (Mil)11.67

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 2 26 13
EPS ($) -2.70 -0.20 -0.69
EPS without NRI ($) -2.70 -0.20 -0.69
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for AEZS

Headlines

Articles On GuruFocus.com
Billionaires Hold Waning Biotechs 42% Off Oct 16 2013 
Can Keryx Succeed Without Partnership? Apr 24 2012 
Keryx Still Has High Potential from Zerenex Apr 12 2012 
Opportunistic Coat-tailing Jan 05 2010 

More From Other Websites
Aeterna Zentaris Announces Zoptrex™ Presentation in Prostate Cancer at 2017 Genitourinary Cancers... Feb 14 2017
Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen™ Feb 13 2017
Aeterna Zentaris to Present at the 2nd Annual Disruptive Growth & Healthcare Conference Feb 09 2017
Aeterna Zentaris to Present at the 2017 BIO CEO and Investor Conference Feb 07 2017
Drug Approvals Expected to Rise as Trump Pledges to Speed Up Approval Process: Latest Reports on... Feb 01 2017
Expectations Run High At AEterna Zentaris Inc. (USA) (AEZS) As Two New Drugs Enter Final Testing... Jan 31 2017
Aeterna Zentaris Announces Completion of Zoptrex™ Pivotal Phase 3 Clinical Trial in Advanced... Jan 30 2017
Biotech Industry Outperforming Markets in 2017: Latest Reports on Pulmatrix and Aeterna Zentaris Jan 18 2017
Dryships, Agile Therapeutics in Thursday’s 52-Week Low Club Jan 05 2017
AEterna Zentaris Inc. (USA) (AEZS) Is Down, But Probably Not Out Jan 05 2017
01.04.2017 Aeterna Zentaris Announces Top-Line Results of Confirmatory Phase 3 Trial of Macrilen™ Jan 04 2017
Aeterna Zentaris Announces Top-Line Results of Confirmatory Phase 3 Trial of Macrilen™ Jan 04 2017
Æterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 15, 2016 Nov 15 2016
Aeterna Zentaris 3Q Loss $6M or 61c/Share (AEZS) Nov 09 2016
AEterna Zentaris Inc. (USA) (AEZS) Lines Up A Binary Event Reversal For The First Quarter Nov 09 2016
11.08.2016 Aeterna Zentaris Reports Third Quarter 2016 Financial and Operating Results Nov 08 2016
Aeterna Zentaris Reports Third Quarter 2016 Financial and Operating Results Nov 08 2016
11.01.2016 Aeterna Zentaris Announces Closing of US$7,560,000 Registered Direct Offering of Common... Nov 01 2016
Aeterna Zentaris Announces Closing of US$7,560,000 Registered Direct Offering of Common Shares and... Nov 01 2016
Here Are Three Big Biotech Movers And Our Take On What’s Next Oct 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)